Drug intelligence / Profile preview

trastuzumab + bortezomib

Development stage: Unknown
Lead developer: Millennium Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of trastuzumab, a monoclonal antibody targeting HER2, and bortezomib, a proteasome inhibitor. This combination has been studied in clinical trials for advanced breast cancer, particularly for patients who have developed resistance to trastuzumab alone. The dual targeting approach aims to enhance anti-tumor effects by simultaneously inhibiting HER2 signaling and proteasome function.

Brand names: Herceptin + Velcade
Other names: trastuzumab + PS-341Herceptin + PS-341

Targets

PSMB5 (Proteasome subunit beta Type-5)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on trastuzumab + bortezomib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trastuzumab + bortezomib.

Explore the full profile